Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph early_phase_1
1
13%
Ph not_applicable
2
25%
Ph phase_2
1
13%
Ph phase_3
2
25%
Ph phase_4
1
13%
Ph phase_1
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)
Other(2)

Detailed Status

Completed3
unknown2
Not yet recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (12.5%)
Phase 11 (12.5%)
Phase 21 (12.5%)
Phase 32 (25.0%)
Phase 41 (12.5%)
N/A2 (25.0%)

Trials by Status

completed338%
unknown225%
not_yet_recruiting225%
terminated113%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8